Figure 6. Systemic treatment of NSC697923 inhibits melanoma xenograft growth, and decreases melanoma tumor growth and malignancy.

(A) Cell growth analysis via MTT assay. A375, A2058, and B16 were treated with varying concentrations of NSC697923 in the presence of 1% or 10% FBS. Graphs represent averages of tetrad wells +/− SD, p-values<0.05 were obtained via unpaired student T-test. (B) Subcutaneous tumor growth kinetics. A375 cells (1.5×10⁵/injection) were injected into both flanks of NSG mice. Animals (n=4/group) were then treated every other day with intraperitoneal dose of 100 μl solvent (5% DMSO in 30% corn oil) or NSC697923 (5 mg/Kg body weight). (C) Images of the subcutaneous tumors collected 22 days after injection. (D) Immunoblotting of protein lysates isolated from subcutaneous tumors for K63-Ub and Actin. (E-J) Immunostaining of the frozen sections of the subcutaneous tumors for Ki-67, cleaved caspase 3, SOX10, Nestin, ABCB5, and p16 [orange]. Nuclei [blue]. Graphs depict quantification of relative percentages or intensities of cells positively stained for the above markers. P-values less than 0.05 were obtained via unpaired student T-test.